KRAS and non-small cell lung carcinoma: In addition, adagrasib (MRTX 849), a potent, covalent KRAS G12C inhibitor, is also being assessed by the FDA for accelerated approval as a treatment for patients with previously treated KRASG12C mutant NSCLC [35].